Poolbeg Pharma Increases Share Capital After Option Exercises

The latest update is out from Poolbeg Pharma Ltd. ( (GB:POLB) ).

Poolbeg Pharma has issued and allotted 7,903,778 new ordinary shares following the exercise of share options by former employees, with admission of the new shares to trading on AIM expected on 3 February 2026. Following this admission, the company’s total shares in issue and voting rights will rise to 705,103,778, a new denominator for investors assessing disclosure thresholds under UK transparency rules.

The most recent analyst rating on (GB:POLB) stock is a Hold with a £4.50 price target. To see the full list of analyst forecasts on Poolbeg Pharma Ltd. stock, see the GB:POLB Stock Forecast page.

Spark’s Take on GB:POLB Stock

According to Spark, TipRanks’ AI Analyst, GB:POLB is a Neutral.

The score is held back primarily by weak financial performance (no revenue, widening losses, and continued cash burn), partially offset by a debt-free balance sheet. Technicals are modestly supportive with neutral momentum, while valuation remains constrained by losses and the absence of a dividend.

To see Spark’s full report on GB:POLB stock, click here.

More about Poolbeg Pharma Ltd.

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on transforming the cancer immunotherapy field. Its lead asset, POLB 001, is designed to make cancer immunotherapies safer by preventing Cytokine Release Syndrome, potentially allowing treatment to move from specialised cancer centres into community hospitals and expanding the eligible patient pool. The company is also developing an oral encapsulated GLP-1 therapy as a more patient-friendly approach to obesity treatment, targeting one of the world’s largest healthcare markets, and aims to partner high-value programmes that address large unmet medical needs.

Average Trading Volume: 1,089,677

Technical Sentiment Signal: Buy

Current Market Cap: £29.63M

For an in-depth examination of POLB stock, go to TipRanks’ Overview page.